Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lesofavumab, an antibody targeting Influenza B Virus.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Duvortuxizumab, an antibody targeting CD19 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Azintuxizumab, an antibody targeting SLAMF7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Aprutumab, an antibody targeting FGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tibulizumab, an antibody targeting TNFSF13B × IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tepoditamab, an antibody targeting CLEC12A × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Samrotamab, an antibody targeting LRRC15.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Onvatilimab, an antibody targeting VSIR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imaprelimab, an antibody targeting MCAM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gimsilumab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cofetuzumab, an antibody targeting PTK7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Abrezekimab, an antibody targeting IL-13.